Despite the regulatory approval of new antiepileptic drugs (AED) over the past decade and the expansion of indications deemed suitable for epilepsy surgery, individuals with intractable seizures – roughly one in three epilepsy patients – still face a dearth of…
Tag Archives: FDA
Omontys Recall Rings Alarm Over Biosimilars
February 27, 2013 – 9:00 am
On the ‘Gom-Boo,’ Ampligen, and Holding Out Hope
February 7, 2013 – 3:12 pm
Don’t Call Them Generics!
January 29, 2013 – 4:19 pm
Biosimilars are Changing the Global Game
January 23, 2013 – 10:01 am
Big Wins, a Cliff, a Race and a Red Face: A 2012 Recap
December 21, 2012 – 9:08 am
FDA’s Confusing Action Against Burzynski – What Does it Really Mean?
November 6, 2012 – 4:07 pm
Caught in Its Own Snare
July 16, 2012 – 2:30 pm
BIO-Buzzwords Won’t Die, So We May as Well Evolve Them
June 25, 2012 – 2:17 pm
A Nightmare on BIO 2012 Exhibition Street
June 19, 2012 – 10:19 am
Join the Conversation